Personalized mRNA Vaccines in Melanoma: Scientific Foundations, Clinical Progress, and Strategic Development

Read full text Summarise with VIRAT
Authors: Madhav Gohel, Peivand Pirouzi
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Personalized messenger ribonucleic acid (mRNA) cancer vaccines are emerging as an important advancement in precision oncology, particularly in the treatment of high-risk melanoma. These vaccines are designed using tumor-specific neoantigens identified through genomic sequencing and bioinformatics, enabling a more targeted and individualized immune response. This article examines the scientific basis, clinical progress, and development strategies associated with this approach. Melanoma, due to its high tumor mutational burden (TMB), is well suited for personalized immunotherapy. Recent advances in mRNA technology and lipid nanoparticle (LNP) delivery systems have supported faster and more flexible vaccine development, with early clinical studies showing promising safety and efficacy, especially when combined with checkpoint inhibitors. The article also applies a Stage-Gate framework to evaluate product development while considering market potential, regulatory pathways, and financial feasibility. Although challenges such as manufacturing complexity, regulatory uncertainty, and high costs remain, personalized mRNA vaccines show strong potential to improve patient outcomes and influence future cancer treatment strategies. Keywords: mRNA vaccines, melanoma, neoantigens, personalized immunotherapy, checkpoint inhibitors, precision oncology, lipid nanoparticles, Stage-Gate framework

Fields of Study & Subjects

Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers Cutaneous Melanoma Detection and Management

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN